Frederick A. Spencer, MD; Jeanna Allegrone, BA; Robert J. Goldberg, PhD; Joel M. Gore, MD; Keith A.A. Fox, MB, ChB, FRCP; Christopher B. Granger, MD; Rajendra H. Mehta, MD; David Brieger, MD; the GRACE Investigators*
Grant Support: GRACE is supported by an unrestricted educational grant from Aventis Pharma, Bridgewater, New Jersey.
Potential Financial Conflicts of Interest:Honoraria: K.A.A. Fox (Aventis, Bristol-Myers Squibb/Sanofi); Grants received: K.A.A. Fox (Aventis, Bristol-Myers Squibb/Sanofi), C.B. Granger (Aventis, Bristol-Myers Squibb/Sanofi, Organon, Novartis, AstraZeneca).
Requests for Single Reprints: Frederick A. Spencer, MD, Department of Medicine/Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655; e-mail, email@example.com.
Current Author Addresses: Drs. Spencer, Goldberg, and Gore and Ms. Allegrone: Department of Medicine/Division of Cardiovascular Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655.
Dr. Fox: The Royal Infirmary of Edinburgh, Department of Cardiology, Edinburgh, Scotland EH3 9WY, United Kingdom.
Dr. Granger: Duke University Medical Center, 2400 Pratt Street, Room 0311, Terrace Level, Box 3409, Durham, NC 27705.
Dr. Mehta: University of Michigan Health System, Division of Cardiology, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0366.
Dr. Brieger: Concord Repatriation Hospital, Coronary Care Unit, Level 3, Multi Building, Hospital Road, Concord NSW 2139, Australia.
Author Contributions: Conception and design: F.A. Spencer, J.M. Gore, C.B. Granger.
Analysis and interpretation of the data: F.A. Spencer, J. Allegrone, R.J. Goldberg, J.M. Gore, K.A.A. Fox.
Drafting of the article: F.A. Spencer, R.J. Goldberg.
Critical revision of the article for important intellectual content: F.A. Spencer, R.J. Goldberg, J.M. Gore, K.A.A. Fox, C.B. Granger, R.H. Mehta, D. Brieger.
Final approval of the article: F.A. Spencer, J. Allegrone, R.J. Goldberg, J.M. Gore, K.A.A. Fox, C.B. Granger, R.H. Mehta, D. Brieger.
Provision of study materials or patients: R.H. Mehta, D. Brieger.
Statistical expertise: J. Allegrone.
Obtaining of funding: J.M. Gore.
Administrative, technical, or logistic support: J.M. Gore.
Spencer F., Allegrone J., Goldberg R., Gore J., Fox K., Granger C., Mehta R., Brieger D., ; Association of Statin Therapy with Outcomes of Acute Coronary Syndromes: The GRACE Study. Ann Intern Med. 2004;140:857-866. doi: 10.7326/0003-4819-140-11-200406010-00006
Download citation file:
Published: Ann Intern Med. 2004;140(11):857-866.
While the benefits of statins in the primary and secondary prevention of coronary artery disease are clear, the value of statin therapy in acute coronary syndromes is uncertain.
Analyzing data from a large, international observational study of acute coronary syndromes, these investigators identified associations between statin use before and during acute coronary events and favorable outcomes.
While these data suggest a potential benefit of statins during acute coronary events, trials are necessary to determine the most appropriate use of statins in the treatment of acute coronary events.
Data from randomized clinical trials support the efficacy of lipid-lowering medications, particularly statins, in the primary and secondary prevention of coronary artery disease (1-3).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Emergency Medicine, Hospital Medicine, Dyslipidemia, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only